Ilaris market forecast points to faster growth through 2030

The Ilaris market is expected to expand as precision immunology, better diagnosis and broader reimbursement improve access to biologic treatments for rare inflammatory diseases. North America led the market in 2025, while Asia-Pacific is projected to grow fastest over the forecast period.

Why it matters: - Ilaris is tied to rare inflammatory and autoinflammatory diseases that can be difficult to diagnose and treat. - Market growth could translate into broader access to biologic therapy for patients with unmet needs, especially as reimbursement and specialist care expand. - Aging populations and rising inflammatory disease prevalence are adding to demand for therapies like Ilaris.

What happened: - The Business Research Company published a 2026 outlook for the global Ilaris market. - The report says the market is set for notable change as treatment advances and understanding of inflammatory disease improves. - The company placed North America as the largest regional market in 2025. - The company expects Asia-Pacific to post the fastest growth during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offers a free sample of the Ilaris market report. - The company also offers the full Ilaris market report.

The details: - Ilaris, or canakinumab, is a monoclonal antibody used to treat inflammatory conditions, including rare autoinflammatory disorders. - Ilaris blocks interleukin-1 beta, a cytokine involved in the inflammation process. - The drug is approved for CAPS, including familial cold autoinflammatory syndrome, and systemic juvenile idiopathic arthritis. - The treatment is used to reduce severe symptoms and complications in patients who do not respond well to standard therapies. - Historical growth came from limited success with conventional anti-inflammatory drugs and unmet needs among patients with cryopyrin-associated periodic syndromes. - Early biologic approvals, specialist prescribing and rising awareness of autoinflammatory syndromes also supported market growth. - Future growth is being driven by precision immunology research, which is improving targeted treatment options for rare inflammatory diseases. - Improved diagnosis rates and expanding reimbursement coverage for biologics are widening access to therapies like Ilaris. - New cytokine-targeting drugs and the growth of specialty rheumatology centers are also supporting demand. - The growing prevalence of inflammatory diseases is expected to increase the patient pool for Ilaris. - A 2023 National Library of Medicine report said inflammatory bowel disease cases in Canada reached about 11,000 newly diagnosed patients, with an incidence rate of 30 per 100,000. - That report projected the Canadian incidence rate to rise 0.58% annually to 32.1 per 100,000 by 2035. - The World Health Organization said in October 2024 that the global population aged 60 and older will rise from 1 billion in 2020 to 1.4 billion by 2030. - The WHO forecast also projects the 60-plus population will reach 2.1 billion by 2050, while those aged 80 and above will triple to 426 million. - The report includes new 2026 features such as market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The report points to a market shaped less by broad anti-inflammatory use and more by precision treatment for rare disease segments. - North America's lead suggests established biologics adoption and specialist networks still matter most for near-term sales. - Asia-Pacific's faster expected growth signals where access expansion and awareness gains may create the next wave of demand.

What's next: - The report says the market will keep tracking advances in precision immunology, reimbursement coverage and specialty care access. - Regional growth will likely hinge on diagnosis improvements and healthcare investment, especially in Asia-Pacific. - More detailed forecasting tools and updated market graphics are now part of the company's 2026 report package.